• +1-646-491-9876
    • +91-20-67278686

    Search

    Apoptosis Regulator BAX-Pipeline Review H1 2017

    Apoptosis Regulator BAX-Pipeline Review H1 2017

    • Report Code ID: RW0001834452
    • Category Pharmaceuticals
    • No. of Pages 44
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Pipeline Review, H1 2017

    Summary

    According to the recently published report 'Apoptosis Regulator BAX - Pipeline Review, H1 2017'; Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) pipeline Target constitutes close to 6 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.

    Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Apoptosis regulator BAX or bcl-2-like protein 4 is a protein is encoded by the BAX gene. It accelerates programmed cell death by antagonizing the apoptosis repressor BCL2. It promotes activation of CASP3, and thereby apoptosis. It undergoes a conformation change that causes translocation to the mitochondrion membrane, leading to the release of cytochrome c that then triggers apoptosis under stress conditions.

    The report 'Apoptosis Regulator BAX - Pipeline Review, H1 2017' outlays comprehensive information on the Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    It also reviewsalso reviews key players involved in Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Oncology, Central Nervous System and Musculoskeletal Disorders which include indications Lung Cancer, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Huntington Disease, Ischemic Cerebral Stroke, Liver Cancer, Melanoma, Muscular Dystrophy, Myocardial Infarction, Parkinson's Disease and Stroke.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX)
    - The report reviews Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Overview
    Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Companies Involved in Therapeutics Development
    Genervon Biopharmaceuticals LLC
    Huons Co Ltd
    Lytix Biopharma AS
    Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Drug Profiles
    GM-6 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HU-010 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LTX-401 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Activate Apoptosis Regulator BAX for Lung Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit BAX for Myocardial Infarction - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SMBA-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Product Development Milestones
    Featured News & Press Releases
    Apr 06, 2017: Lytix Biopharma presents poster on LTX-401 at AACR in Washington April 2017
    Mar 23, 2017: Confidential Data from Genervon ALS Phase 2A Clinical Trial Were Released and Published
    Jan 10, 2017: Genervon Releases ALS, PD and AD DiseaseĀ­ Associated Gene Lists Modulated by GM6 and Encourages Researchers to Explore New Discoveries beyond Single Target Drug Development Paradigm
    Dec 27, 2016: ALS and Alzheimer's disease bioinformatics reports confirm GM6's role as regulator of disease-relevant pathways
    Sep 21, 2016: Lytix Biopharma develops second generation oncolytic molecules for deep seated tumors
    Jun 06, 2016: GENERVON GM604 received EUs orphan drug designation to treat ALS
    May 23, 2016: ALS Patients from Around the World Responding Well to Genervons GM604
    May 03, 2016: GM604 to Be Granted "Orphan Drug" Status in Europe
    Sep 22, 2015: Genervon GM604 Reduced TDP-43 Protein Aggregates and Slowed Down ALS Progression
    Jun 29, 2015: Genervon Filed Patent for Using GM604 Modulations of ALS Disease Biomarkers Showing Homeostasis, Leading to Prognosis and Therapeutic Treatment for ALS Disease
    Apr 17, 2015: Amyotrophic Lateral Sclerosis Statement; FDA
    Jan 08, 2015: Genervon Announces ALS Compassionate Use Results
    Oct 19, 2014: Genervon Announces ALS and PD Phase 2a Trial Results
    Jun 30, 2014: Genervon Announces Biomarker Data from GALS-001 Clinical Trial for ALS
    Apr 28, 2014: Genervon Successfully Completes its Phase 2a Clinical Trial for ALS
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Genervon Biopharmaceuticals LLC, H1 2017
    Pipeline by Huons Co Ltd, H1 2017
    Pipeline by Lytix Biopharma AS, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Genervon Biopharmaceuticals LLC
    Huons Co Ltd
    Lytix Biopharma AS

    Request for Sample

    Report Url http://www.reportsweb.com//apoptosis-regulator-bax-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//apoptosis-regulator-bax-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//apoptosis-regulator-bax-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments